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Cardiovascular disease modelsHuman heart disease is a major cause of death and
disability. A variety of animal models of cardiac disease
have been developed to better understand the etiol-
ogy, cellular and molecular mechanisms of cardiac
dysfunction and novel therapeutic strategies. The ani-
mal models have included large animals (e.g. pig and
dog) and small rodents (e.g. mouse and rat) and the
advantages of genetic manipulation in mice have
appropriately encouraged the development of novel
mouse models of cardiac disease. However, there are
major differences between rodent and human hearts
that raise cautions about the extrapolation of results
from mouse to human. The rabbit is a medium-sized
animal that has many cellular and molecular charac-
teristics very much like human, and is a practical alter-
native to larger mammals. Numerous rabbit models of
cardiac disease are discussed, including pressure or
volume overload, ischemia, rapid-pacing, doxorubicin,
drug-induced arrhythmias, transgenesis and infection.
These models also lead to the assessment of therapeu-
tic strategies which may become beneficial in human
cardiac disease.
Why rabbit models?
The study of human cardiovascular disease has been greatly
facilitated by the use of awide variety of animalmodels. Small
animal models such as rodents, guinea pigs and hamsters
offer many advantages (low cost, short gestation time and*Corresponding authors: : S.M. Pogwizd (spogwizd@cardmail.dom.uab.edu), D.M. Bers
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short time for disease progression). Furthermore, there is a
tremendous amount of historical data over decades in rat
models of cardiovascular disease.Moreover, the development
of genetically modified mice has transformed medical
research, allowing investigators to overexpress, knock-out
or knock-in genes of interest to explore the functional con-
sequences of such genetic modulation.
Large animal disease models, such as in dog and pig, offer
distinct advantages. Larger hearts provide a considerable
amount of tissue (from different chambers and regions of the
heart) for biochemical and molecular studies. Hemodynamic
assessment and imaging is easier, the heart is large enough for
chronic instrumentation or for in vivo cardiacmapping studies,
and large size allows assessment of human-scale interventions
ranging from left ventricular assist devices (LVADs), implanta-
blecardiacdefibrillators (ICDs),cardiacresynchronizationther-
apy (CRT) and cardiac ablative approaches. Moreover, larger
animal hearts have physical dimensions more like human
hearts, and this larger size may be crucial for some arrhythmo-
genic mechanisms. However, the cost (both purchase cost and
per diem charges) can be prohibitive, especially for long-term
chronic studies in disease states.
Because of its intermediate size, the rabbit offers several
potential advantages over other species. Although the rabbit
heart is smaller than that of dog or pig, it is large enough to
easily do surgical and catheter-based interventions at a much
lower cost (5–15 times less expensive than those of dogs). At185
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been or are being scaled down for pediatric use and assess-
ment (e.g. pacemakers and CRT) so that rabbit models can be
beneficial (see below). Surgical interventions are still easier
thanmicrosurgical approaches in rodents. More importantly,
rabbit cardiac physiology has more characteristics that are
similar to human cardiac physiology than mouse or rat has.
Indeed, cellular electrophysiology and Ca2+ transport in
rabbit are muchmore like those in human than is the case for
either rat or mouse [1]. This is particularly relevant for the
studies of heart failure (HF) and arrhythmias because altera-
tions in ion channel and Ca2+ transporter function or expres-
sion are thought to contribute directly to depressed
contractile performance and arrhythmogenesis [2,3]. In par-
ticular,mouse and rat ventricular action potentials (APs) have
very short duration and completely lack the prominent AP
plateau phase typical of human, rabbit and most mammals
larger than that of rat (Fig. 1D). Furthermore, the main ionic
currents underlying repolarization and which greatly influ-
ence AP duration (APD) are the same in human and rabbitFigure 1. Ca2+ fluxes and action potentials in rabbit and rat ventricular myocytes
rabbit and rat ventricular myocytes, on the basis of quantitative analysis of Ca2+ r
combined slow action of the plasma membrane Ca-ATPase (SL Ca-ATPase) and
(C) In rabbit HF, enhanced NCX function and decreased SR function brings these
Human nonfailing and failing hearts exhibit similar balance of fluxes as in rabbit [6]
myocytes (data from Bassani et al. [105]) indicating the K+ currents responsib
186 www.drugdiscoverytoday.com(delayed rectifier K+ currents IKr and IKs). These channels are
not present in mouse or rat, where APD is dictated almost
entirely by transient outward currents (Ito). Ito is present in
human and rabbit ventricle, but plays only a minor role in
APD in human and rabbit. Notably, the electrophysiological
characteristics and secondary regulation of Ito versus IKr and
IKs are completely different, making this much more than a
quantitative difference.
In mouse and rat, almost all of the Ca2+ involved in the
activation of contraction is released from the sarcoplasmic
reticulum (SR), and during relaxation almost all of that Ca2+ is
resequestered by the SR via the SR Ca-ATPase (Fig. 1A, much
like in skeletal muscle). However, in human and rabbit ven-
tricular myocytes a considerably larger fraction of activating
Ca2+ comes via Ca2+ entry, and the same amount is extruded
at each beat by the electrogenic Na/Ca exchange [1]. Under
control conditions in rabbit and human this is 24–30% of the
Ca2+ involved in excitation–contraction coupling, and in HF
the SR and trans-sarcolemmal cycling can be nearly equal
(Fig. 1B,C; [4–6]). Because changes in SR Ca2+ content and. (A) and (B) Integrated Ca2+ fluxes during [Ca2+]i decline in normal adult
emoval fluxes by the SR Ca-ATPase (SR) Na/Ca exchange (NCX) and the
mitochondrial uniporter (Mito; on the basis of data in Bassani et al. [105]).
systems into more equal contribution (based on data in Pogwizd et al. [4]).
. (D)Action potentials recorded in normal adult rabbit and rat ventricular
le for repolarization at different phases (Ito, IKs and IKr).
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Table 1. Rabbit models of heart disease
Experimental conditions Refs
(a) Volume overload
Arterio-venous shunt formation [8]
Aortic regurgitation [9,10]
(b) Models of ventricular hypertrophy
Chronic AV block [12]
Chronic infusion of angiotensin [18]
LV pressure overload
Aortic constriction [13–15]
Nephrectomy (hypertension) [16,17]
RV pressure overload
Pulmonary artery constriction – adult [19]
Pulmonary artery constriction – young [20]
Monocrotaline-induced pulmonary hypertension [21]
(c) Ischemic heart disease models
Myocardial infarction in the rabbit
Coronary artery occlusion [23,24]
Myocardial ischemia followed by reperfusion [27]
Intracoronary microsphere embolization [28]
Direct current shock [30]
Hibernating myocardium
Coronary artery ligation [31]
Cellular model [32]
(d) Heart failure
Adriamycin cardiomyopathy [37–39]
High-dose catecholamines [42]
Pacing-induced heart failure [44–47]
Combined pressure and volume overload [5,52,54,59,61]
(e) In vivo arrhythmia models
Torsades des pointes [62–65]
Atrial fibrillation
Isolated rabbit atria prep [67–69]
Ventricular tachypacing-induced HF [71]
(f) Transgenic rabbit models of heart disease
Long QT syndrome [72]
Hypertrophic cardiomyopathy [73,74]
Gsa overexpression [75]
Phospholamban overexpression [76]
(g) Other rabbit cardiac models
Myocarditis
Viral (coronavirus and coxsackie virus) [77,78]
Fungal (Cryptococcus) [79]
Parasitic (toxoplasmosis) [80]
Bacterial (streptococci and diphtheria) [81,82]
Chronic Chagas disease (Trypanosoma cruzi) [83,84]
Bacterial endocarditis (streptococcus,
enterococcus and staphylococcus)
[85]
Radiation-induced heart disease [87]release, SR Ca-ATPase function and Na/Ca exchange influ-
ence both contractile function (systolic and diastolic) and
arrhythmogenesis in HF, this major fundamental species
difference may be crucial not only for the end-point pheno-
type, but also for the adaptive/maladaptive mechanisms
involved in disease progression.
Adult mouse and rat ventricles normally express mainly
the fast a-myosin isoform (which allows faster crossbridge
cycling and muscle shortening than b-myosin), but during
hypertrophy and HF there is isoform switching to b-myosin
[7]. Adult human and rabbit myocardia express almost
entirely b-myosin so there is little room for further isoform
switching (although the change may still have functional
consequences). These various differences are not arguments
against other large animal models (e.g. canine and porcine,
which resemble human and rabbit in this regard), but are
crucial when extrapolating results frommouse and rat hearts
in the context of human disease.
In the rest of this review, we discuss specific rabbit models
of heart disease (rabbit models of vascular disease, lipid
disorders, diabetes mellitus, thyroid disease, obesity or
chronic hypoxia are not addressed). Although constrained
by space, we attempt to provide an overview of the range of
rabbit heart disease models used, along with some of their
methods, advantages, limitations and potential (see Table 1).
Volume overload
Arterio-venous (AV) shunt formation can induce volume
overload (e.g. by side-by-side anastamosis of the common
carotid artery and the external jugular vein). This leads to
cardiac hypertrophy, but there are little data on effects on LV
contractile function [8].
Aortic regurgitation (AR) also causes volume overload, and
can be induced in rabbits by aortic valve cusp perforation
with a catheter using a transcarotid approach [9]. Severe AR
leads to left ventricular hypertrophy that is followed by LV
systolic dysfunction and HF over the course of one to two
years. Although not all AR rabbits develop HF, this represents
an advantage over ARmodels in other species such as dog that
consistently manifest normal systolic function (for review,
see [9]). Chronic AR rabbits exhibit myocardial fibrosis pre-
ceding the development ofHF, in large part because of cardiac
fibroblasts that produce abnormal proportions of noncolla-
gen extracellular matrix, specifically fibronectin, with little
change in collagen synthesis [10].
Models of ventricular hypertrophy
Chronic AV block
Chronic AV block in the dog (induced by AV nodal ablation)
leads to ventricular remodeling characterized by LV hyper-
trophy and electrical remodeling [11]. A similar model, devel-
oped in the rabbit heart, exhibits electrical remodeling with
prolonged QT interval, spontaneous torsades des pointes(TdP) in 75% of bradypaced rabbits, reduced IKs and IKr,
and downregulated KvLQT1, minK and HERG [12].
Pressure overload
Aortic constriction (ascending or descending) in adult rabbits
results in LV hypertrophy (typically on the order of 35–50%)www.drugdiscoverytoday.com 187
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aorta of infant (ten-day-old) rabbits (a model analogous to
coarctation of the aorta seen in children) leads to progressive
aortic stenosis, and within six to seven weeks LV mass/
volume ratios increases by 30–100% (without change in
LV systolic function), but with decreased myocyte contrac-
tility [14,15].
Hypertension can induce left ventricular hypertrophy in
the rabbit when unilateral nephrectomy is combined with
either contralateral renal artery constriction or renal wrap-
ping. As an example, studies in the one-kidney, one-clip
(1K,1C) Goldblatt rabbit (removal of the right kidney and
partial constriction of the left renal artery) demonstrated
severe hypertension, a 75% increase in LV mass, and dia-
stolic dysfunction (LV systolic function was preserved) [16].
Mild LV hypertrophy has also been produced in rabbit by a
one-kidney, one-wrap method [17]. In other studies, chronic
infusion of angiotensin has been used to induce hypertension
[18].
RV pressure overload can also induce right heart hyper-
trophy (and HF). This has been induced in rabbits by several
interventions including pulmonary artery constriction in
adult [19] or young rabbits [20] and monocrotaline-induced
pulmonary hypertension [21].
Ischemic heart disease models
Myocardial infarction (MI) in the rabbit can be induced by
coronary artery occlusion, and this is a useful model. There
are some differences in coronary anatomy between rabbits
and other species. The collateral circulation is not as exten-
sive as it is in the canine heart, and the circumflex supplies
most of the LV free wall and is more dominant than the left
anterior descending (LAD) coronary artery [22,23]. As such,
the occlusion of the marginal branch of the circumflex
coronary artery is often used for MI induction, and leads to
mild to moderate degrees of HF, with LV ejection fractions
in the range of 40–50%, but in some studies EFs were as low
as 27% [23,24]. MIs are characterized by increased LV end-
diastolic dimension and increased left atrial size, similar to
that found in LAD infarcts in other species. There are
significant alterations in b-adrenergic receptor (b-AR) sig-
naling including global reduction in b-AR density, reduced
b-AR coupling and increased protein levels and activity of
bARK1 and Gi [25]. There is regional heterogeneity of
intracellular Ca2+ handling [23] and impaired synchroniza-
tion of Ca2+ release events throughout the myocytes [26].
In addition to chronic occlusion, a rabbit model of myo-
cardial ischemia followed by reperfusion has been used
[27]. Moreover, other rabbit MI models include intracor-
onary microsphere embolization [28] (similar to a well-
established intracoronary microembolization model in
dog) [29], and direct current-shock-induced cardiac muscle
injury [30].188 www.drugdiscoverytoday.comHibernating myocardium models in the rabbit have been
developed, for example with coronary artery ligation [31].
Moreover, a cellular model of hibernating myocardium in
rabbit cardiacmyocytes has been developed [32]. Coculturing
of adult rabbit cardiomyocytes with cardiac fibroblasts
induced hibernation-like dedifferentiation and serves as a
valuable tool to study cellular pathways of hibernating myo-
cardium in vitro.
Rabbit models of heart failure
HF has been induced in the rabbit heart by several
approaches. As mentioned above, volume or pressure over-
load, as well as MI, occasionally leads to HF. However, several
HF rabbit models have been developed using approaches that
have been successful in other animal species [33–35].
Doxorubicin (Adriamycin), an anthracycline chemother-
apeutic agent, is one of themost prescribed anticancer drugs,
primarily because of its effectiveness in a wide variety of
hematologic malignancies and solid tumors. However, car-
diotoxicity is a major clinical problem, and its cumulative
toxicity on myocardium prevents their use at maximum
doses that would be needed for optimal treatment [36].
Progressive reduction in ejection fraction is seen during
the course of therapy, and life threatening CHF is observed
in 10% of patients receiving more than 550 mg/m2. This
has prompted studies in experimental models. Adriamycin
has been used experimentally to induce cardiomyopathy in
rabbits [37–39]. This model has been useful in identifying
cardioprotective agents that could limit adriamycin toxicity.
It has also been useful as amodel of nonischemic cardiomyo-
pathy with severe cardiac dilatation, LV hypertrophy, and
decreased LV systolic function that is progressive and irre-
versible, accompanied by fluid retention and activation of
the sympathetic nervous system and the renin–angiotensin
systems [37]. However, there is no evidence of b-adrenergic
receptor downregulation as occurs in advanced human HF
[40]. Cardiotoxicity is due to free radical formation and lipid
peroxidation that ultimately alters lysosomes, mitochon-
dria, SR and the sarcolemmal membrane. These changes
result in the activation of hydrolytic enzymes, calcium over-
load and reduced energy production [41]. Pathologic
changes including cytosolic vacuolization and myofibrillar
loss are typical of adriamycin cardiotoxicity in patients, but
are different from those observed in other forms of nonis-
chemic HF in humans (e.g. idiopathic dilated cardiomyo-
pathy (IDCM), long-standing hypertension or valvular heart
disease). Other limitations include the variable degree of LV
dysfunction produced, undesirable bone marrow and GI
toxicity.
High-dose catecholamines (isoproterenol or epinephrine),
repetitively infused, induce a cardiomyopathy in rabbits
characterized by LV dilation, hypertrophy and depressed
systolic function, but a high mortality rate [42].
Vol. 5, No. 3 2008 Drug Discovery Today: Disease Models | Cardiovascular disease modelsRapid pacing induces HF. Tachycardia-induced HF has
been described in patients with long-standing tachyar-
rhythmias such as atrial fibrillation (AF) with rapid ventri-
cular response. As such, rapid pacing (whether ventricular
or atrial) has been used to induce HF in several species –
most commonly dog, but also pig and rabbit [43]. Rapid
ventricular pacing in the rabbit induces HF characterized by
cardiac enlargement, systolic dysfunction and ventricular
myocytes exhibiting contractile dysfunction. The inter-
mediate size of the rabbit allows implantation of standard
human pacemakers. Because the intrinsic heart rates of
rabbits are in the range of 220–280 beats/min, pacing to
rates in the range of 340–400 beats/min are required [44–
46]. HF develops over the course of two to five weeks and is
characterized by dyspnea, appetite loss and body weight
loss. Chronic pacing leads to progressive, predictable and
time-dependent reduction in LV systolic function and geo-
metry [44], which allow the study of molecular and cellular
events during the development of chronic HF. Develop-
ment of HF is associated with reduced responsiveness to
inotropic stimulus, decreased myocyte contractility, and
neurohumoral activation [44,47]. There are changes in
Ca2+ homeostatic mechanisms consistent with human
HF, including decreases in Ca transient amplitude, L-type
Ca2+ channel activity and SERCA expression. However, Yao
et al. report decreased Na/Ca exchange current in pacing HF
rabbits [45] in contrast to studies in canine pacing HF
showing enhanced NCX activity when [Ca2+]i was mini-
mally buffered [48]. As with pacing HF models in other
species, LV systolic function returns to normal within
approximately one week following cessation of pacing,
although adenyl cyclase response to agonists takes two
weeks, and b-adrenergic receptor density takes four weeks
to return to normal [46]. Moreover, the LV dilatation and
dysfunction is not associated with myocardial or cellular
hypertrophy [44], so the changes in LVmyocardial structure
are not similar to those of clinical HF in humans caused by
ischemic or hypertensive heart disease. The model has
nonetheless provided important information regarding
the pathophysiology of the failing heart including electrical
remodeling [49], abnormal intracellular Ca2+ cycling [50]
and exercise training in HF [51].
Many of the rabbit heart disease models provide investi-
gators with hypertrophied and/or failing myocardium with
which to study alterations such as contractile dysfunction,
myocardial energetics and gene expression. However, the
studies of arrhythmogenesis in the failing heart in these
models are limited by the fact that few of these rabbit models
are truly arrhythmogenic. In fact, even when one considers
other animal models of HF, both large and small, there are
few models that exhibit both severe contractile dysfunction
and spontaneously occurring and inducible ventricular
arrhythmias.Combining volume overload (AR) with pressure overload
(aortic constriction) several weeks later consistently leads to
HF (much more so than either volume or pressure overload
alone) [52]. We have demonstrated that HF rabbits exhibit
severely depressed LV function with LVH (75% increase in
HW/BW), spontaneously occurring VT that initiates by a
nonreentrant mechanism such as triggered activity, and a
10% incidence of sudden death [5,53,54]. We also showed
that HF rabbit myocytes exhibit contractile dysfunction from
decreased SR Ca load that is associated with altered intracel-
lular Ca handling ("NCX, #RyR and preserved SERCA); pre-
served b-AR responsiveness with enhanced b2-AR
responsiveness; decrease in ion currents (Ito, IK1 and IKs);
activation (by catecholamines) of a transient inward current
Iti that can initiate delayed after depolarizations (DADs);
downregulation and dephosphorylation of the main ventri-
cular gap junctional protein connexin43 (Cx43) increased
the expression and activation of CaMKII and increased RyR
phosphorylation and SR Ca2+ leak [3,5,53,55,56]. Many of
these findings have been validated by focused studies in
failing human hearts including 3D mapping studies showing
focal nonreentrant mechanisms underlying VT in patients
with nonischemic HF, NCX upregulation with preserved
SERCA in a large subset of human HF patients, enhanced
b2-adrenergic responsiveness in failing human cardiac myo-
cytes [53,57,58], and Cx43 downregulation and dephosphor-
ylation in human HF (both ischemic and nonischemic) [55].
Other studies with this HF model have demonstrated addi-
tional insights into arrhythmogenesis [59], sinus node dys-
function in HF [60] and the effects of acute ischemia
superimposed on chronic HF [61]. Thus, findings in these
models have provided important new insights into human
HF. While this arrhythmogenic rabbit model of nonischemic
HF is technically challenging and takes months to develop,
the similarities of rabbit myocardium to humanmyocardium
and validating studies in humans indicate that this model
provides important insights into the contractile dysfunction
and arrhythmogenicity of the failing heart.
Other in vivo arrhythmia models
TdP, a polymorphic ventricular tachycardia that occurs in the
setting of a prolonged QT interval, can be caused by several
pharmaceutical agents (primarily those that inhibit IKr, the
rapid component of the inward rectifying potassium current,
IKr). TdP had been difficult tomodel in experimental animals,
and mouse and rat which lack an AP plateau and IKr are less
useful animal models in this arena. Carlsson et al. [62] first
developed an in vivo model of TdP in the anesthetized a-
adrenoreceptor (a-AR)-stimulated rabbit (methoxamine plus
the Class III antiarrhythmic clofilium). This model has been
used extensively by several groups with minor modification
[62–64] to test for drug-induced TdP, to understand the
underlying electrophysiological mechanisms [65] or towww.drugdiscoverytoday.com 189
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remains unclear as to how a-AR stimulation facilitates TdP
induction, but could involve increases in [Ca2+]i, elevation of
blood pressure or reflex vagal nerve activation [64]. Myocar-
dial failure in the rabbit (induced by coronary artery ligation)
has also been used as a model to predict the development of
TdP [66].
AF can be studied in isolated rabbit atria preparations, and
this has provided key insights into the mechanism of AF
[67,68] and the role of atrial dilatation [69]. Rabbit models
of heart disease have been used to study atrial conduction and
atrial fibrillation. Chronic volume overload from AV shunt
formation slowed atrial conduction and enhanced the induc-
tion of atrial tachycardia (but not AF) [70]. However, rabbits
with ventricular tachypacing-induced HF exhibit atrial fibro-
sis and enhanced atrial fibrillation induced by burst pacing
[71].
Transgenic rabbit models of heart disease
Transgenic mice have provided important insights into cel-
lular physiology, but the small size of murine hearts limits
easy assessment of function and precluding assessment of
human-size interventions such as pacing, CRT and defibrilla-
tion. However, in the past decade, transgenic rabbits have
been developed, combining the value of transgenic
approaches (overexpression or knock-outs of key genes, pre-
viously restricted to the mouse) with the larger animal size,
and the scale and physiology of the rabbit.
Transgenic rabbit models created to date include: long QT
syndrome [72], hypertrophic cardiomyopathy [73,74], Gsa
overexpression [75] and phospholamban overexpression
[76]. In some cases, findings in transgenic rabbits appear
different from those in transgenic mice. For example, trans-
genic rabbits overexpressing the G proteinGsa do not develop
cardiomyopathy like their transgenic mouse counterparts
[75]; and phospholamban overexpressing transgenic rabbits
have normal cardiac function and response to b-adrenergic
stimulation, unlike transgenic mouse models [76]. These
findings might arise from species differences in compensa-
tory changes and/or species differences in cellular physiology
(rabbit calcium handling and ion channel physiology is
closer to that of human than what is observed in mouse).
The expense and time for the development of transgenic
rabbits has been limiting, but with further advances in the
field, transgenic rabbits will offer important insights into
cardiac physiology. Moreover, the addition of induced car-
diac disease states (such as pressure overload, MI and HF) will
provide novel insights into contractile dysfunction, cardiac
remodeling and arrhythmogenesis.
Other cardiac models
Infectious diseases affecting the heart have stimulated several
experimental models in the rabbit. Myocarditis (with HF and190 www.drugdiscoverytoday.comdilated cardiomyopathy) has been induced in rabbits infected
with viruses such as coronavirus and coxsackie virus [77,78],
fungi such as Cryptococcus [79], parasites such as toxoplas-
mosis [80] and bacteria such as streptococci [81] and
diphtheria [82]. Chronic Chagas disease has been produced
in rabbits by the inoculation of a virulent strain of Trypano-
soma cruzi, and is characterized by biventricular (bi-V) dilata-
tion and hypertrophy, apical aneurysm, interstitial fibrosis
and focal myocarditis [83,84]. Bacterial endocarditis has been
produced in rabbit with several bacterial pathogens including
streptococcus, enterococcus and staphylococcus [85].
Although the focus of these studies is predominantly in
response to antimicrobial therapy, these models have pro-
vided insight into pathogenesis of both native valve and
prosthetic valve endocarditis in humans. Sepsis affects car-
diac function, and endotoxin-induced cardiomyopathy has
been induced by the infusion of bacterial lipopolysaccharide
[86].
Radiation also induces acutemyocardial lesions, typically a
pancarditis with inflammatory exudates, followed by a latent
phase and eventually myocardial and pericardial fibrosis [87].
Studies in rabbits have also shown that radiation enhances
adriamycin cardiotoxicity [88].
Assessment of therapeutic approaches in rabbit
heart models
Having discussed a large number of rabbit models of heart
disease, we finish this review with a brief discussion of how
these models have been and can be used in the development
of novel therapeutic approaches to heart disease.
Drug therapy with different pharmacologic agents as ther-
apy for HF has been used in a wide range of rabbit heart
models – primarily in infarct and combined pressure and
volume overload models, but to some degree in pacing-
induced and adriamycin-induced HF.
Cardiac ablative therapy in the rabbit heart is limited by
the small size for in vivo studies using currently utilized
ablation catheters. However, the isolated perfused rabbit
heart has been useful for characterizing the effects of radio-
frequency ablation (of atrium, ventricle and AV node) on
conduction and the underlying anatomy [89,90].
CRT also known as bi-V pacing is beginning to be applied to
the rabbit model of MI. Recent studies have shown that bi-V
pacing attenuated LV dilatation, systolic dysfunction and
electrical remodeling [91].
ICDs have not been used in rabbit models to date. How-
ever, VF inducibility and VF threshold have been assessed in
the in vivo rabbit heart [92] as well as in the Langendorff-
perfused rabbit heart [93].
Gene therapy approaches have been used in the rabbit
models of heart disease. Direct intramuscular injection of
viral vectors into rabbit LV myocardium is the simplest
approach, but is limited by local transgene expression as well
Vol. 5, No. 3 2008 Drug Discovery Today: Disease Models | Cardiovascular disease modelsas traumatic effects from needle injections. Myocardial gene
delivery approaches to rabbits initially involved thoracot-
omy-based approaches: delivery of adenoviral transgenes
either by ex vivo (retrograde) intracoronary delivery to donor
hearts of a heterotopic heart transplant model [94] or LV
cavity injection (with ascending aorta cross-clamped) [95].
However, noninvasive techniques such as percutaneous sub-
selective coronary artery catheterization have resulted in the
efficient delivery of transgene that is ventricle-specific and
targeted to the particular coronary artery that is catheterized
[96]. Koch and his colleagues used these approaches to
demonstrate that adenoviral gene transfer to overexpress
the b2-adrenergic receptor or bARKct (a peptide inhibitor
of b-adrenergic receptor kinase 1 (bARK1)) in the rabbit MI
model can enhance contractile function and b-adrenergic
receptor responsiveness, and delay the onset of HF [95–97].
Other studies in rabbit include have explored adenoviral gene
transfer of sodium–calcium exchanger (NCX) [98]; fibroblast
growth factor-2 [28], caspase inhibitor p35 [99], norepinephr-
ine transporter uptake-1 [100], extracellular superoxide dis-
mutase [101] and of the antiapototic factor Bcl-2 [24].
Cell therapy approaches are being tested in rabbit heart.
Examples of recent studies include skeletal myoblast trans-
plantation in the infarcted rabbit heart [102], and autologous
stem cell transplantation in doxorubicin-induced nonis-
chemic HF [103,104].
Conclusion
There are no ideal models of heart disease, and every model
utilized has both advantages and disadvantages. The rabbit
has been used to develop models of a wide variety of human
diseases including pressure overload, volume overload, com-
bined pressure and volume overload, pacing-induced HF,
toxic cardiomyopathy, toxic cardiomyopathy, MI and trans-
genic rabbit models. Transgenic rabbit models of heart dis-
ease have been developed for several human diseases and
more are on the way. Rabbit models of human heart disease
can offer distinct advantages over rodent or large animal
(dogs and pigs) in terms of intermediate size, intermediate
costs and similarities to human physiology, and can provide
novel insights into human cardiac disease.
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